1268314-73-3

Upstream product

• 1257327-82-4 N₁-(cyclopropylmethyl)-4-methoxybenzene-1,2-diamine 
• 1268314-71-1 1-(cyclopropylmethyl)-1H-benzotriazol-5-ol 
• 1257327-83-5 1-(cyclopropylmethyl)-5-methoxy-1H-benzotriazole 
• 1041593-38-7 N-(cyclopropylmethyl)-4-methoxy-2-nitroaniline 
• 96-96-8 4-methoxy-2-nitroaniline 
• 1268314-72-2 1-(cyclopropylmethyl)-4-iodo-1H-benzotriazol-5-ol 
• 100-39-0 benzyl bromide 

Downstream Products

• 1268314-74-4 5-(benzyloxy)-1-(cyclopropylmethyl)-4-(trifluoromethyl)-1H-benzotriazole 
• 1408245-05-5 1-{4-[1-(cyclopropylmethyl)-4-(trifluoromethyl)-1H-benzotriazol-5-yl]benzyl}-3-methylimidazolidine-2,4-dione 

Relevant academic research and scientific papers

ETHER BENZOTRIAZOLE DERIVATIVES

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

ALKYNE BENZOTRIAZOLE DERIVATIVES

The present invention is directed to alkyne benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES

The present invention is directed to aminomethyl biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

CYCLOHEXENE BENZOTRIAZOLE DERIVATIVES

The present invention is directed to cyclohexene benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

HYDROXYMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES

The present invention is directed to hydroxymethyl biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

ETHER BENZOTRIAZOLE DERIVATIVES

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.